Compass Pathways reports Q3 2025 results with cash position of $185.9 million

Reuters

2025/11/04

Compass Pathways reports Q3 2025 results with cash position of $185.9 million

Compass Pathways plc reported a cash and cash equivalents position of $185.9 million as of September 30, 2025, up from $165.1 million at December 31, 2024. Debt stood at $31.3 million, compared to $30.2 million at year-end 2024. Research and development expenses for the nine months ended September 30, 2025, were $88.5 million, a slight increase from $86.9 million in the same period of 2024, mainly due to expenses related to late-stage COMP360 phase 3 clinical trials. The company expects full year 2025 net cash used in operating activities to be between $120 million and $145 million, and anticipates its cash position will fund operations into 2027. Compass Pathways is accelerating its commercialization plans for COMP360 in treatment-resistant depression by 9-12 months, following the completion of COMP006 trial enrollment and positive discussions with the FDA regarding NDA submission strategies.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Compass Pathways plc published the original content used to generate this news brief via Business Wire (Ref. ID: 20251104736485) on November 04, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2580078097"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2580078097\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2580078097?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-04 19:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2580078097","market":"fut","top_or_hot":-1,"title":"Compass Pathways reports Q3 2025 results with cash position of $185.9 million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Compass Pathways reports Q3 2025 results with cash position of $185.9 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Compass Pathways plc reported a cash and cash equivalents position of $185.9 million as of September 30, 2025, up from $165.1 million at December 31, 2024. Debt stood at $31.3 million, compared to $30.2 million at year-end 2024. Research and development expenses for the nine months ended September 30, 2025, were $88.5 million, a slight increase from $86.9 million in the same period of 2024, mainly due to expenses related to late-stage COMP360 phase 3 clinical trials. The company expects full year 2025 net cash used in operating activities to be between $120 million and $145 million, and anticipates its cash position will fund operations into 2027. Compass Pathways is accelerating its commercialization plans for COMP360 in treatment-resistant depression by 9-12 months, following the completion of COMP006 trial enrollment and positive discussions with the FDA regarding NDA submission strategies.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Compass Pathways plc published the original content used to generate this news brief via Business Wire (Ref. ID: 20251104736485) on November 04, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Compass Pathways reports Q3 2025 results with cash position of $185.9 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCompass Pathways reports Q3 2025 results with cash position of $185.9 million\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-11-04 19:30</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Compass Pathways reports Q3 2025 results with cash position of $185.9 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Compass Pathways plc reported a cash and cash equivalents position of $185.9 million as of September 30, 2025, up from $165.1 million at December 31, 2024. Debt stood at $31.3 million, compared to $30.2 million at year-end 2024. Research and development expenses for the nine months ended September 30, 2025, were $88.5 million, a slight increase from $86.9 million in the same period of 2024, mainly due to expenses related to late-stage COMP360 phase 3 clinical trials. The company expects full year 2025 net cash used in operating activities to be between $120 million and $145 million, and anticipates its cash position will fund operations into 2027. Compass Pathways is accelerating its commercialization plans for COMP360 in treatment-resistant depression by 9-12 months, following the completion of COMP006 trial enrollment and positive discussions with the FDA regarding NDA submission strategies.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Compass Pathways plc published the original content used to generate this news brief via Business Wire (Ref. ID: 20251104736485) on November 04, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CMPS","symbol_name":"COMPASS Pathways plc","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251104:nNDL8r5Kz:1","article_id":"2580078097","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2580078097","pubTimestamp":1762255847,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Compass Pathways plc reported a cash and cash equivalents position of $185.9 million as of September 30, 2025, up from $165.1 million at December 31, 2024. Debt stood at $31.3 million, compared to $30.2 million at year-end 2024. Research and development expenses for the nine months ended September 30, 2025, were $88.5 million, a slight increase from $86.9 million in the same period of 2024, mainly due to expenses related to late-stage COMP360 phase 3 clinical trials. The company expects full year 2025 net cash used in operating activities to be between $120 million and $145 million, and anticipates its cash position will fund operations into 2027. Compass Pathways is accelerating its commercialization plans for COMP360 in treatment-resistant depression by 9-12 months, following the completion of COMP006 trial enrollment and positive discussions with the FDA regarding NDA submission strategies.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CMPS":"COMPASS Pathways plc","BK4139":"生物科技"},"translate_title":"Compass Pathways公布2025年第三季度业绩，现金头寸为1.859亿美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CMPS":0.9},"content_text":"Compass Pathways reports Q3 2025 results with cash position of $185.9 million\n    \n\n        Compass Pathways plc reported a cash and cash equivalents position of $185.9 million as of September 30, 2025, up from $165.1 million at December 31, 2024. Debt stood at $31.3 million, compared to $30.2 million at year-end 2024. Research and development expenses for the nine months ended September 30, 2025, were $88.5 million, a slight increase from $86.9 million in the same period of 2024, mainly due to expenses related to late-stage COMP360 phase 3 clinical trials. The company expects full year 2025 net cash used in operating activities to be between $120 million and $145 million, and anticipates its cash position will fund operations into 2027. Compass Pathways is accelerating its commercialization plans for COMP360 in treatment-resistant depression by 9-12 months, following the completion of COMP006 trial enrollment and positive discussions with the FDA regarding NDA submission strategies.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Compass Pathways plc published the original content used to generate this news brief via Business Wire (Ref. ID: 20251104736485) on November 04, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}